Trial Profile
A Phase 1, Single-Center, Dose-Escalation and Fixed-Dose Crossover, Cohort Study to Determine the Safety and Pharmacokinetics of a Single Oral Dose of PF329 versus oral hydromorphone hydrochloride (HCl) in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Jul 2019
Price :
$35
*
At a glance
- Drugs Hydromorphone (Primary)
- Indications Pain
- Focus Adverse reactions; Pharmacokinetics
- 24 Jun 2011 Primary endpoint 'Pharmacokinetic-parameters' has been met.
- 26 Apr 2011 New trial record